Pharmerica Corporation (NYSE:PMC) was downgraded by equities researchers at Barrington Research from an “outperform” rating to an “underperform” rating in a report issued on Wednesday. Barrington Research also issued estimates for Pharmerica Corporation’s Q4 2018 earnings at $0.59 EPS.

A number of other research analysts have also weighed in on PMC. BidaskClub lowered shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. UBS AG reissued a “neutral” rating and issued a $29.25 target price (up from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. KeyCorp lowered shares of Pharmerica Corporation to an “overweight” rating in a research note on Wednesday, August 2nd. Credit Suisse Group lowered shares of Pharmerica Corporation from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $28.95 to $19.20 in a research note on Friday, August 4th. They noted that the move was a valuation call. Finally, Zacks Investment Research lowered shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $25.48.

Shares of Pharmerica Corporation (NYSE PMC) opened at 28.95 on Wednesday. The company has a market capitalization of $910.19 million, a PE ratio of 39.23 and a beta of 0.92. The firm’s 50-day moving average price is $26.08 and its 200 day moving average price is $24.81. Pharmerica Corporation has a 52 week low of $19.20 and a 52 week high of $29.00.

Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.47. The firm had revenue of $592 million for the quarter, compared to analyst estimates of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. Pharmerica Corporation’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period last year, the company posted $0.47 EPS. Equities analysts predict that Pharmerica Corporation will post $1.91 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Barrington Research Lowers Pharmerica Corporation (PMC) to Underperform” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/barrington-research-lowers-pharmerica-corporation-pmc-to-underperform.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Pharmerica Corporation during the fourth quarter worth $3,864,000. Teachers Advisors LLC raised its position in Pharmerica Corporation by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 357,845 shares of the company’s stock worth $9,000,000 after buying an additional 16,715 shares during the period. Louisiana State Employees Retirement System raised its position in Pharmerica Corporation by 0.8% in the first quarter. Louisiana State Employees Retirement System now owns 12,500 shares of the company’s stock worth $293,000 after buying an additional 100 shares during the period. Candriam Luxembourg S.C.A. raised its position in Pharmerica Corporation by 9.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 72,000 shares of the company’s stock worth $1,685,000 after buying an additional 6,000 shares during the period. Finally, Fisher Asset Management LLC raised its position in Pharmerica Corporation by 32.6% in the first quarter. Fisher Asset Management LLC now owns 70,707 shares of the company’s stock worth $1,655,000 after buying an additional 17,395 shares during the period. 92.84% of the stock is currently owned by institutional investors and hedge funds.

About Pharmerica Corporation

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.